SCHEMBL5879181

SCHEMBL5879181

Cc1ccc2[nH]c3c4c(=O)[nH]c(=O)c4c4c(=O)[nH]c(=O)c4c3c2c1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHEK1 O14757 6/20 0.82
ALDH1A1 P00352 6/20 0.54
KDM4E B2RXH2 7/20 0.48
MEN1 O00255 3/20 0.48
KMT2A Q03164 3/20 0.48
GAA P10253 2/20 0.48
GLA P06280 1/20 0.48
NPC1 O15118 3/20 0.47
POLB P06746 1/20 0.47
MAPT P10636 3/20 0.46
RXFP1 Q9HBX9 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
ROCK2 O75116 1/20 0.46
PARP1 P09874 1/20 0.46
HSD17B10 Q99714 4/20 0.45
TSHR P16473 1/20 0.45
HTT P42858 1/20 0.45
LMNA P02545 3/20 0.45
HPGD P15428 3/20 0.45
SMN1; SMN2 Q16637 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5879256 0.86 CHEK1 (0.63) CHEK1ALDH1A1MAPTRXFP1
SCHEMBL21563915 0.80 MEN1 (0.61) CHEK1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL5879297 0.79 CHEK1 (0.59) CHEK1ALDH1A1MAPTPARP1HSD17B10
SCHEMBL5879160 0.79 CHEK1 (0.82) CHEK1MEN1KMT2AGAAPOLB
SCHEMBL5879153 0.79 CHEK1 (0.59) CHEK1ROCK2PARP1
SCHEMBL5879244 0.79 CHEK1 (0.59) CHEK1ALDH1A1KDM4EGAAGLA
SCHEMBL5879303 0.79 CHEK1 (0.59) CHEK1KDM4EMEN1KMT2AGAA
SCHEMBL5879238 0.79 PDGFRB (0.62) CHEK1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL29022540 0.77 CHEK1 (0.56) CHEK1ALDH1A1KDM4EMEN1KMT2A
SCHEMBL13412884 0.76 MEN1 (0.65) CHEK1ALDH1A1KDM4EMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7151108-B2 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATORIES SERVIER (FR) 2006-12-19 US disclosed
EP-1411057-B1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them SERVIER LAB (FR) 2005-04-27 EP disclosed
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents LES LABORATOIRES SERVIER (FR) 2004-04-22 US disclosed
EP-1411057-A1 [3,4-a:3,4-c]carbazole derivatives, process for their preparation and pharmaceutical compositions containing them Les Laboratoires Servier (FR) 2004-04-21 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040077672-A1 Anticarcinogenic, antiproliferative, and antitumor agents XDH, TOP2A, TOP1 CHEK1 943/4885ALDH1A1 286/4885KDM4E 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.